Tradestie Institutional Equity Comparison Engine

LAZR vs SGMO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SGMO Overall Edge

SGMO Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sangamo Therapeutics, Inc. Common Stock (SGMO) driven by superior Valuation, Growth & Margin, Options & Structure while LAZR counters with relative strength in Momentum & Technical. Fundamentally, LAZR trades at N/M Forward P/E with -340.9% operating margin (+21.0% YoY revenue) versus SGMO at 0.4x Forward P/E and -175.5% operating margin (+88.4% YoY). In options structure, LAZR sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against SGMO sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner SGMO
LAZR N/M vs SGMO 0.4x Fwd P/E
Growth & Margin Winner SGMO
Op Margin -340.9% vs -175.5% ยท YoY +21.0% vs +88.4%
Momentum & Technical Winner LAZR
1Y +469.8% vs -76.0% ยท 52W Pos 53% vs 9%
Options & Structure Winner SGMO
BREAKDOWN (8th %ile IV) vs UNCLASSIFIED (71st %ile IV)
LAZR NASDAQ
Luminar Technologies, Inc. Class A Common Stock
Motor Vehicle Parts & Accessories
$27.12
-7.28% 1D
Market Cap $14.7M
1M Return -25.51%
1Y Return +469.75%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 58.0 Mom 70.0
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
1M Return -40.82%
1Y Return -76.04%
Forward P/E 0.4x
Unified AI Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LAZR +469.75% SGMO -76.04% Spread: +94.98 pp (SGMO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LAZR TTM Op. Margin: -340.9% SGMO TTM Op. Margin: -175.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LAZR vs SGMO. Trailing 12-month operating profitability (LAZR -340.9% vs SGMO -175.5%) and valuation multiples (LAZR N/M vs SGMO 0.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LAZR (3) vs SGMO (6)
Institutional Metric LAZR SGMO Criterion Row Winner
Market Capitalization Scale $14.7M $55.9M Larger Scale SGMO
Trailing P/E Ratio Valuation N/M 0.4x Lower Multiple SGMO
Forward P/E Ratio Valuation N/M 0.4x Lower Multiple SGMO
Revenue Growth (YoY) Growth +21.0% +88.4% Higher Growth SGMO
Operating Margin (TTM) Profitability -340.9% -175.5% Higher Margin SGMO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -2424.7% -2891.8% Higher ROE LAZR
52-Week Range Position Momentum 53% ($0โ€“$51) 9% ($0โ€“$1) Stronger Trend LAZR
Beta / 30D Volatility Risk Regime 3.66ฮฒ ยท 99% Vol 1.49ฮฒ ยท 206% Vol Lower Realized Risk LAZR
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 52.0 / 100 (HOLD) Higher Composite SGMO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LAZR vs SGMO Buy Guide
LAZR BREAKDOWN
97d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live LAZR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SGMO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 71st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live SGMO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LAZR nor SGMO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.